A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule With a Zika Virus Purified Inactivated Vaccine Plus Alum Adjuvant in Healthy Adults

Trial Profile

A Phase 1, Randomized, Double-Blind Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of an Accelerated Vaccination Schedule With a Zika Virus Purified Inactivated Vaccine Plus Alum Adjuvant in Healthy Adults

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs Zika virus vaccine-Sanofi (Primary)
  • Indications Zika virus infection
  • Focus Adverse reactions
  • Acronyms Z001
  • Most Recent Events

    • 05 Dec 2017 Preliminary results assessing the early safety and immunogenicity of Zika-virus-vaccine in the phase I trials (NCT02963909, NCT02952833, and NCT02937233; n=68) published in The Lancet.
    • 27 Sep 2017 Planned End Date changed from 1 Feb 2018 to 1 Apr 2018.
    • 27 Sep 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top